Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | UBE2M | P61081 | 2/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188342 | 0.84 | PTGDR2 (0.41) | PTGDR2TBXA2RPTGDRPSIP1 | |
| SCHEMBL12002786 | 0.80 | CYP2C9 (0.36) | PTGDR2TBXA2RPTGDRCYP2C9PSIP1 | |
| SCHEMBL15006653 | 0.80 | PTGDR2 (0.44) | PTGDR2TBXA2RPTGDRCYP2C9DRD2 | |
| SCHEMBL15428828 | 0.79 | PTGDR2 (0.60) | PTGDR2TBXA2RPTGDRCYP2C9DRD2 | |
| SCHEMBL12002746 | 0.77 | PTGDR (0.36) | PTGDR2TBXA2RPTGDRCYP2C9PSIP1 | |
| SCHEMBL15436288 | 0.75 | PTGDR (0.39) | PTGDR2TBXA2RPTGDRCYP2C9 | |
| SCHEMBL2189056 | 0.75 | PTGDR2 (0.41) | PTGDR2TBXA2RPTGDRPSIP1 | |
| SCHEMBL15436284 | 0.74 | CYP2C9 (0.33) | PTGDR2TBXA2RPTGDRCYP2C9PSIP1 | |
| SCHEMBL2187311 | 0.71 | DRD2 (0.32) | PTGDR2TBXA2RPTGDRCYP2C9DRD2 | |
| SCHEMBL2188128 | 0.70 | KMT2A (0.41) | PTGDR2TBXA2RDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885TBXA2R 28/4885PTGDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.